Atrial fibrillation was present in 47% of patients with cardiac amyloidosis, with a notably higher prevalence in wild-type ATTR-CA (80%) compared to AL-CA (33%).
Cohort (n=108)
What is the prevalence, clinical impact, and what are the predictors of atrial fibrillation in patients with cardiac amyloidosis?
Atrial fibrillation is highly prevalent in cardiac amyloidosis, particularly in wild-type ATTR-CA, and is associated with older age, worse heart failure symptoms, and reduced LVEF.
Absolute Event Rate: 80% vs 33%
Cardiac amyloidosis (CA) frequently coexists with atrial fibrillation (AF), but the extent and impact of this relationship remain unclear. This study investigates the prevalence of AF in CA, compares clinical characteristics between amyloid light-chain (AL)-CA and amyloid transthyretin (ATTR)-CA, and assesses the implications for treatment strategies. We conducted a retrospective analysis of 108 patients with confirmed CA, categorizing them into 2 groups: 51 with AF and 57 with sinus rhythm (SR). We compared demographic, clinical, and echocardiographic data, as well as treatment modalities and outcomes between AL-CA and ATTR-CA subgroups. AF was present in 47% of the cohort, with a notably higher prevalence in wild-type ATTR-CA (80%) compared to AL-CA (33%). Patients with AF were older (73.8 ± 8.5 years) than those with SR (67.7 ± 10.6 years, P < .001) and had more severe heart failure symptoms, comorbidities, and echocardiographic abnormalities, including reduced left ventricular ejection fraction (LVEF; 47% vs 53%, P = .003) and higher pulmonary artery pressures (41 ± 11 mm Hg vs 35 ± 17 mm Hg, P = .02). Logistic regression identified BMI (OR 1.2, 95% CI: 1.05-1.57, P = .02) and eGFR (OR 0.91, 95% CI: 0.92-0.99, P = .04) as independent predictors of AF. CHA2DS2-VASc scores were higher in ATTR-CA patients (4.5 ± 1.2) compared to AL-CA (2.4 ± 1.1, P < .001). Despite a high rate of anticoagulation (78%), ischemic stroke or TIA incidence was low at 6% over 12 months. AF is highly prevalent in CA, particularly in ATTR-CA, and is associated with more severe clinical manifestations. The findings highlight the necessity for systematic AF screening and tailored management strategies in CA patients. Prospective, randomized studies are essential to establish optimal AF treatment protocols in this population.
Rehman et al. (Fri,) conducted a cohort in Cardiac amyloidosis (n=108). Wild-type ATTR-CA vs. AL-CA was evaluated on Prevalence of atrial fibrillation. Atrial fibrillation was present in 47% of patients with cardiac amyloidosis, with a notably higher prevalence in wild-type ATTR-CA (80%) compared to AL-CA (33%).